Credo Diagnostics Biomedical

🌍💚 Today is World Mental Health Day! At Credo Diagnostics Biomedical, we believe that taking care of your mental health is just as important as your physical well-being. It's a time to reflect on how we support ourselves and each other in managing stress, finding balance, and promoting a positive mindset. Whether it's a walk in nature, meditation, connecting with loved ones, or simply taking a break from your screen - every little action matters! How do you take care of your mental health? Share your tips in the comments below. 🙌 #WorldMentalHealthDay #MentalHealthAtWork #WorkplaceWellness #Empowerment #CredoCares #CredoDiagnostics 

Celebrating the Independence Days of Costa Rica, Honduras, Chile, and Mexico! Congratulations to all our partners and the wonderful people of these nations! 🎉   A special thank you to our distribution partners Alatheia, CTR Scientific, Dimex Médica, Servio Sarmiento, Tecno Diagnóstica, Sigma QC for their invaluable support in bringing our innovative medical devices to the LATAM region. Together, we are enhancing healthcare and improving patient outcomes. 🤝   We are also excited to announce our latest product, VitaSIRO 𝘴𝘰𝘭𝘰™, designed to drive advancements in diagnostics across the region. Stay tuned for more updates!   #IndependenceDay #LATAM #HealthcareInnovation #CredoDiagnostics #MedicalDevices #Partnership

💡Did you know? Human Papillomavirus (#HPV) refers to a group of over 200 known viruses and is one of the most common viral infections worldwide. It’s responsible for more than 95% of cervical cancer cases. Cervical cancer is the 4th most common cancer among women globally, with over 600,000 new cases diagnosed each year. While most HPV infections do not cause serious issues, certain high-risk strains can lead to genital warts or cancer. Despite these alarming statistics, regular screening and early detection can significantly reduce the incidence and mortality rates of cervical cancer. At Credo Diagnostics Biomedical, we are developing a molecular #HPV assay designed to detect the 14 high-risk HPV strains in just 45 minutes at the Point-of-Care. We are committed to advancing global health and making a meaningful impact in this critical area. #HPV #CervicalCancer #WomensHealth #GlobalHealth #PoinofCare #MolecularDiagnostics #CancerAwareness #CredoDiagnostics 

Have you ever wondered what goes into developing diagnostic technology? Here’s your chance to take a peek behind the scenes! At Credo Diagnostics Biomedical, our R&D and manufacturing teams work tirelessly to bring innovative diagnostic solutions to life. From initial research to precision manufacturing, every step is meticulously executed to meet the highest lab quality standards. Check out this exclusive glimpse into our labs and facilities, where our talented team makes breakthroughs happen daily. https://lnkd.in/g6ExcDEe #RD #Manufacturing #CredoDiagnostics #AdvancedTechologyforAll 

🌬😷 As the severe winter season approaches in the northern hemisphere, it’s essential to stock up and be ready for the heightened demand for diagnostics. 📈 At Credo Diagnostics Biomedical, our advanced solutions like VitaPCR™ assays are specifically designed to help you manage the surge in testing needs during the winter months. Don’t wait until it is too late – secure your supply now to meet customer demands and make the most of this peak season. 👉 Reach out to our team at service@credodxbiomed.com to place your orders and ensure you are fully equipped for the months ahead! Contact us: https://lnkd.in/gmjzgWCu #Respiratory #WinterPreparedness #PeakSeason #PartnerSuccess #VitaPCR™ #CredoDiagnostics

We're excited to share that our VitaPCR™ SARS-CoV-2 assays can effectively detect the latest SARS-CoV-2 variants, including the XEC variant, which is expected to become more prevalent soon. #XEC is a recombinant hybrid strain of KS.1.1 and KP.3.3 from the Omicron family, as reported by the Centers for Disease Control and Prevention, BBC News, and USA TODAY. It's already spreading across Europe and the US. At Credo Diagnostics Biomedical, we ensure that our detection technology stays ahead of these emerging variants. Stay confident with our reliable and testing solutions. For more details, check out our full statement https://lnkd.in/gFdUazxt or contact us at 𝐬𝐞𝐫𝐯𝐢𝐜𝐞@𝐜𝐫𝐞𝐝𝐨𝐝𝐱𝐛𝐢𝐨𝐦𝐞𝐝.𝐜𝐨𝐦. #covid19 #CredoDiagnostics #VitaPCR #moleculardiagnostics #healthcare

🔔 Big News from Credo Diagnostics Biomedical! Credo is set to begin US clinical trials for the VitaSIRO 𝘴𝘰𝘭𝘰™ — a point-of-care molecular diagnostic system that delivers lab-quality results for SARS-CoV-2, Flu A/B, and RSV. With plans for FDA 510(k) clearance and entry into the US market, this Singapore-based company is poised to advance near-patient testing, offering lab-quality results in 40-45 minutes. Featuring advanced connectivity and a compact design, it’s ready to transform respiratory testing. 👉 Click to learn more about the tech, trials, and Credo's future plans! https://lnkd.in/gUqwnAe5

According to the European Centre for Disease Prevention and Control (ECDC)'s Week 38 Communicable Disease Threats Report, the rate of Acute Respiratory Infections (ARI) is rising in six countries, including Belgium, Czechia, Germany, Lithuania, Luxembourg, and Slovenia. Belgium, the Netherlands, and Slovakia are experiencing an upward trend in test positivity. Additionally, both Czechia and Slovakia have reported an increase in hospitalized patients testing positive for SARS-CoV-2.   Romania and Sweden are experiencing rising trends in ICU admissions and inpatient cases, while deaths related to SARS-CoV-2 have increased in Bulgaria, Czechia, Hungary, Malta, Poland, Romania, and Sweden over the past few weeks. What stands out is that the trend in 2024 is remarkably similar to that of 2023, according to data from ERVISS. This suggests that we must remain vigilant and prepared for what lies ahead. At Credo Diagnostics Biomedical, we are deeply committed to public health and ready to meet this year’s challenges. If you're looking for ways to address the upcoming flu season, feel free to reach out to us at 𝐬𝐞𝐫𝐯𝐢𝐜𝐞@𝐜𝐫𝐞𝐝𝐨𝐝𝐱𝐛𝐢𝐨𝐦𝐞𝐝.𝐜𝐨𝐦. We are eager to share our solutions and provide advanced technologies to support you. #PublicHealth #RespiratoryInfections #FluSeason #GlobalHealth #HealthTrends #PandemicPreparedness #CredoDiagnostics *𝘌𝘙𝘝𝘐𝘚𝘚: 𝘛𝘩𝘦 𝘌𝘶𝘳𝘰𝘱𝘦𝘢𝘯 𝘙𝘦𝘴𝘱𝘪𝘳𝘢𝘵𝘰𝘳𝘺 𝘝𝘪𝘳𝘶𝘴 𝘚𝘶𝘳𝘷𝘦𝘪𝘭𝘭𝘢𝘯𝘤𝘦 𝘚𝘶𝘮𝘮𝘢𝘳𝘺

Patient safety begins with accurate diagnostics. This World Patient Safety Day reminds us of the critical role of precision diagnostics in ensuring the right treatment is delivered at the right time. One of the leading causes of patient harm is diagnostic errors, which can lead to delayed or incorrect treatments.  In recognition of the importance of timely and accurate diagnoses, the theme for World Patient Safety Day is "Improving Diagnosis for Patient Safety." The World Health Assembly and the Global Patient Safety Action Plan 2021–2030 have emphasized the urgent need to improve the safety and reliability of diagnostic processes. Diagnostic errors are a significant issue, contributing to nearly 16% of preventable harm in healthcare systems globally. With most adults expected to experience at least one diagnostic error during their lifetime, enhancing the safety and accuracy of diagnostic practices is essential.  At Credo Diagnostics Biomedical, we are committed to reducing these errors by providing healthcare professionals with reliable, rapid, and accurate diagnostic tools. Our solutions empower clinical decision-making, ensuring patients receive timely treatment and improving overall patient outcomes.  As we observe World Patient Safety Day, let’s continue working together to improve diagnostic accuracy, reduce errors, and ultimately safeguard patient safety. #WorldPatientSafetyDay #PatientSafety #AccurateDiagnostics #QualityCare #BetterOutcomes #CredoDiagnostics